Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Abbott Japan Takes Over Marketing Approval for Duphaston from Daiichi Sankyo
April 2, 2014
- Kyowa Kirin Files Nesp in Japan for Anemia in Myelodysplastic Syndrome
April 2, 2014
- Japan Vaccine Files NDA for Pneumococcal Conjugate Vaccine in Japan
April 2, 2014
- US Biotech NPS Takes Aim at Japan Debut around 2017
April 1, 2014
- Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
- Otsuka Acquires Rights for Dacogen from Eisai US Subsidiary
April 1, 2014
- Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
- AnGes MG to Procure 500 Million Yen through Allocation of New Shares to Third Party, to Invest in Orphan Drug Licensing
March 31, 2014
- Suglat Tops February “Mind Share” Ranking in GP Market
March 31, 2014
- Uniform Pricing of Generics into 3 Price Brackets Will Make It More Difficult to Set Invoice Prices: Pres. Yoshiwaka of Daiichi Sankyo Espha
March 28, 2014
- Takeda, Otsuka to Copromote Takeda’s Novel Acid-Related Disease Treatment Vonoprazan
March 28, 2014
- Cetirizine Generics to Carry 3 Prices, Down from 13: Jiho Tally
March 27, 2014
- Qualified Bidders Selected in 1st Qol-Led Open Tender
March 27, 2014
- PII Study of Anti-PCSK9 Antibody in Japanese Patients Meets Primary Endpoint: Amgen Astellas
March 27, 2014
- Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho
March 26, 2014
- DSP’s Antipsychotic Agent Latuda Gets OK in Australia
March 26, 2014
- MHLW Approves Toyama Chemical’s Novel Anti-Influenza Drug Avigan Tablets
March 26, 2014
- Mitsui Becomes Largest Shareholder of Fuji Pharma through Capital, Business Alliance
March 26, 2014
- Otsuka’s Samsca Approved in Japan as World’s 1st ADPKD Treatment
March 26, 2014
- Novartis Will Not Sell Rasilamlo Blood Pressure Drug in Japan
March 26, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…